lymphatic filariasis / dengue
lymphatic filariasis
Provision of medicine to treat lymphatic filariasis free of charge |
In November 2010, Eisai agreed to provide 2.2 billion tablets of diethylcarbamazine (DEC), a medicine for treating lymphatic filariasis, to the World Based on that agreement, Eisai used its factory in India to manufacture DEC tablets, and began providing them to In February 2016, a new public-private partnership has been initiated to provide In February 2016, a new public-private partnership has been initiated to provide diagnostic kits free of charge, for use in evaluating the success of mass drug administration (MDA) in LF elimination and helping to determine when MDA can stop. Through the supply of DEC tablets and diagnostic kits, Eisai is contributing to the global program to eliminate lymphatic filariasis. More information is avalilable at |
|---|---|
| Development of medicine for treating Filariasis | Eisai commenced research in collaboration with the Liverpool School of Tropical Medicine and the University of Liverpool to jointly identify new drugs The goal is to develop a treatment that can effectively eradicate the worms that cause filariasis. The goal is to develop a treatment that can effectively eradicate the worms that cause filariasis by first eliminating theWolbachia bacteria inside them which the worms (filariae) depend upon for growth, development and survival. The goal is to develop a treatment that can effectively eradicate the worms that cause filariasis by first eliminating theWolbachia bacteria inside them which the worms (filariae) depend upon. |
dengue
| Development of vaccine for treating dengue fever | Takeda is conducting a pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial to evaluate the safety and efficacy of two Takeda is conducting a pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial to evaluate the safety and efficacy of two doses of Takeda's dengue vaccine candidate (TAK-003) in the prevention of laboratory-confirmed symptomatic dengue fever due to any of the four dengue virus serotypes in children and adolescents.
The 18-month data analysis from the pivotal Phase 3 TIDES trial includes an update on overall vaccine efficacy (VE) and a formal assessment of secondary efficacy endpoints by serotype, baseline serostatus and disease severity (18 months after the second dose, which was administered three months after the first dose), demonstrating protection against Takeda plans to share results from the 24-month analysis of TIDID Takeda plans to share results from the 24-month analysis of TIDES in later 2020. Takeda's dengue vaccine candidate is not currently licensed anywhere in the world (as of Takeda plans to share results from the 24-month analysis of TIDES in later 2020.) |
|---|